Vor Biopharma Inc. (VOR) 10-Year Financial Performance & Capital Metrics

VOR • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

AboutVor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Show more

Revenue $0
EBITDA -$118M +4.0%
Net Income -$117M +0.8%
EPS (Diluted) -34.00 +2.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -94.52% -60.9%
ROIC -90.18% -84.5%
Debt/Equity 0.33 +39.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.5x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-2078.1%

EPS CAGR

10Y-

5Y-

3Y-

TTM-1072.82%

ROCE

10Y Avg-452.6%

5Y Avg-65.83%

3Y Avg-54.86%

Latest-76.09%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.66B	105.24	701.60	14.76%	24.69%	25.55%	1.21%	0.01
TGTXTG Therapeutics, Inc.	4.88B	30.71	204.73	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.62B	27.80	2.39	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.48M	3.65	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	21.37M	1.04	-0.41	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	308.06M	14.06	-0.41			-94.52%		0.33
FATEFate Therapeutics, Inc.	121.12M	1.05	-0.64	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	121.95M	6.66	-0.71	-0.55%	-87.43%

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-
Cost of Goods Sold+	20K	91K	0	0	8.96M	3.49M	0
COGS % of Revenue	-	-	-	-	-	-	-
Gross Profit+	-20K	-91K	0	0	-8.96M	-3.49M	0
Gross Margin %	-	-	-	-	-	-	-
Gross Profit Growth %	-	-3.55%	1%	-	-	0.61%	1%
Operating Expenses+	2.86M	10.33M	43.37M	69.02M	84.46M	122.54M	121.19M
OpEx % of Revenue	-	-	-	-	-	-	-
Selling, General & Admin	427K	4.13M	11.75M	21.49M	19.91M	31.72M	27.88M
SG&A % of Revenue	-	-	-	-	-	-	-
Research & Development	2.43M	6.2M	31.62M	47.53M	64.55M	94.31M	93.31M
R&D % of Revenue	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	-3.49M	0
Operating Income+	-2.86M	-10.42M	-43.37M	-69.02M	-93.42M	-126.04M	-121.19M
Operating Margin %	-	-	-	-	-	-	-
Operating Income Growth %	-	-2.64%	-3.16%	-0.59%	-0.35%	-0.35%	0.04%
EBITDA+	-2.84M	-10.33M	-42.76M	-67.58M	-84.46M	-122.54M	-117.66M
EBITDA Margin %	-	-	-	-	-	-	-
EBITDA Growth %	-	-2.64%	-3.14%	-0.58%	-0.25%	-0.45%	0.04%
D&A (Non-Cash Add-back)	20K	91K	605K	1.43M	8.96M	3.49M	3.53M
EBIT	-3.15M	-10.23M	-43.37M	-69.02M	-92.09M	-117.86M	-121.19M
Net Interest Income+	0	-454K	29K	119K	1.32M	8.17M	4.27M
Interest Income	0	154K	29K	119K	1.32M	8.17M	4.27M
Interest Expense	1M	608K	0	0	0	0	0
Other Income/Expense	-1.29M	-422K	29K	119K	1.32M	8.17M	4.27M
Pretax Income+	-4.15M	-10.84M	-43.34M	-68.9M	-92.09M	-117.86M	-116.91M
Pretax Margin %	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%
Net Income+	-4.15M	-10.84M	-43.34M	-68.9M	-92.09M	-117.86M	-116.91M
Net Margin %	-	-	-	-	-	-	-
Net Income Growth %	-	-1.61%	-3%	-0.59%	-0.34%	-0.28%	0.01%
Net Income (Continuing)	-4.15M	-10.84M	-43.34M	-68.9M	-92.09M	-117.86M	-116.91M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-14.60	-6.20	-26.60	-37.80	-46.60	-35.00	-34.00
EPS Growth %	-	0.58%	-3.29%	-0.42%	-0.23%	0.25%	0.03%
EPS (Basic)	-14.60	-6.20	-26.60	-37.80	-46.60	-35.00	-34.00
Diluted Shares Outstanding	283.02K	1.86M	1.86M	1.86M	1.98M	3.36M	3.44M
Basic Shares Outstanding	283.02K	1.86M	1.86M	1.86M	1.98M	3.36M	3.44M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	936K	7.54M	49.11M	214.4M	236.95M	140.8M	96.51M
Cash & Short-Term Investments	929K	6.47M	48.54M	207.47M	230.25M	137.18M	91.93M
Cash Only	929K	6.47M	48.54M	119.8M	57.71M	31.36M	81.95M
Short-Term Investments	0	0	0	87.67M	172.54M	105.81M	9.98M
Accounts Receivable	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	0	205K	100K	2.09M	2.34M	475K	380K
Total Non-Current Assets+	71K	2.29M	26.8M	28.19M	62.42M	69.03M	46.38M
Property, Plant & Equipment	71K	728K	21.84M	22.52M	57.08M	50.1M	41.59M
Fixed Asset Turnover	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	0	1.56M	1.56M	0	2.41M	2.41M	0
Other Non-Current Assets	0	0	3.4M	5.67M	2.92M	4.81M	4.8M
Total Assets+	1.01M	9.83M	75.91M	242.59M	299.37M	209.83M	142.89M
Asset Turnover	-	-	-	-	-	-	-
Asset Growth %	-	8.76%	6.73%	2.2%	0.23%	-0.3%	-0.32%
Total Current Liabilities+	7.77M	2.19M	10.21M	10.15M	13.12M	15.57M	18.61M
Accounts Payable	38K	693K	2.36M	1.54M	1.77M	815K	1.5M
Days Payables Outstanding	693.5	2.78K	-	-	72.19	85.19	-
Short-Term Debt	4.46M	0	863K	0	0	3.83M	0
Deferred Revenue (Current)	1000K	0	0	0	0	0	0
Other Current Liabilities	3.19M	900K	4.26M	434K	4.95M	4.96M	0
Current Ratio	0.12x	3.45x	4.81x	21.12x	18.06x	9.04x	5.19x
Quick Ratio	0.12x	3.45x	4.81x	21.12x	18.06x	9.04x	5.19x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	17.43M	16.17M	35.64M	43.53M	27.61M
Long-Term Debt	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	17.43M	16.17M	35.64M	31.83M	27.61M
Deferred Tax Liabilities	0	0	0	0	0	11.7M	0
Other Non-Current Liabilities	0	0	0	0	0	0	0
Total Liabilities	7.77M	2.19M	27.64M	26.33M	48.76M	59.1M	46.23M
Total Debt+	4.46M	0	18.29M	18.01M	38.91M	35.66M	31.83M
Net Debt	3.53M	-6.47M	-30.25M	-101.79M	-18.79M	4.3M	-50.12M
Debt / Equity	-	-	0.38x	0.08x	0.16x	0.24x	0.33x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-2.85x	-17.13x	-	-	-	-	-
Total Equity+	-6.77M	7.64M	48.27M	216.26M	250.61M	150.72M	96.66M
Equity Growth %	-	2.13%	5.32%	3.48%	0.16%	-0.4%	-0.36%
Book Value per Share	-23.91	4.12	26.00	116.35	126.72	44.86	28.14
Total Shareholders' Equity	-6.77M	7.64M	48.27M	216.26M	250.61M	150.72M	96.66M
Common Stock	0	0	1K	4K	7K	7K	13K
Retained Earnings	-7.05M	-17.89M	-61.22M	-130.12M	-222.22M	-340.08M	-456.99M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	-770K	-77K	22K
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.66M	-9.86M	-36.29M	-69.14M	-85.14M	-100.29M	-99.66M
Operating CF Margin %	-	-	-	-	-	-	-
Operating CF Growth %	-	-2.7%	-2.68%	-0.91%	-0.23%	-0.18%	0.01%
Net Income	-4.15M	-10.84M	-43.34M	-68.9M	-92.09M	-117.86M	-116.91M
Depreciation & Amortization	20K	91K	605K	1.43M	2.52M	3.49M	3.53M
Stock-Based Compensation	116K	172K	1.34M	4.32M	10.7M	13.36M	9.85M
Deferred Taxes	289K	0	0	0	0	0	0
Other Non-Cash Items	1M	576K	782K	3.19M	6.42M	67K	3.87M
Working Capital Changes	63K	145K	4.32M	-9.19M	-12.69M	650K	5K
Change in Receivables	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	65K	0	0	405K	0	2.85M	2.24M
Cash from Investing+	0	-748K	-4.16M	-91.65M	-94.09M	71.01M	96.86M
Capital Expenditures	0	-748K	-4.16M	-3.89M	-8.46M	-1.07M	-229K
CapEx % of Revenue	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0
Cash from Financing+	2.46M	17.7M	82.53M	232.91M	117.14M	2.94M	53.39M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	0	7K	259K	-1.66M	1.17M	-1.64M	-2.43M
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-2.66M	-10.6M	-40.45M	-73.04M	-93.61M	-101.36M	-99.89M
FCF Margin %	-	-	-	-	-	-	-
FCF Growth %	-	-2.98%	-2.82%	-0.81%	-0.28%	-0.08%	0.01%
FCF per Share	-9.40	-5.71	-21.79	-39.29	-47.33	-30.17	-29.08
FCF Conversion (FCF/Net Income)	0.64x	0.91x	0.84x	1.00x	0.92x	0.85x	0.85x
Interest Paid	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-2483.16%	-155.02%	-52.09%	-39.45%	-58.74%	-94.52%
Return on Invested Capital (ROIC)	-	-	-338.81%	-78.13%	-40.47%	-48.87%	-90.18%
Debt / Equity	-	-	0.38x	0.08x	0.16x	0.24x	0.33x
Interest Coverage	-2.85x	-17.13x	-	-	-	-	-
FCF Conversion	0.64x	0.91x	0.84x	1.00x	0.92x	0.85x	0.85x

Frequently Asked Questions

Growth & Financials

Vor Biopharma Inc. (VOR) grew revenue by 0.0% over the past year. Growth has been modest.

Vor Biopharma Inc. (VOR) reported a net loss of $2.45B for fiscal year 2024.

Dividend & Returns

Vor Biopharma Inc. (VOR) has a return on equity (ROE) of -94.5%. Negative ROE indicates the company is unprofitable.

Vor Biopharma Inc. (VOR) had negative free cash flow of $144.7M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener